Ultragenyx Pharmaceutical Inc Insider Trading
Every director, officer and 10% holder of Ultragenyx Pharmaceutical Inc has to report each trade in its stock within two business days of making it. This is those filings.
RARE on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Theodore Alan HuizengaSVP, Chief Accounting Officer2026-09-151.3K shat $13.57 | Sale10b5-1 plan | $17.4K |
| Theodore Alan HuizengaSVP, Chief Accounting Officer2026-09-03161 shat $13.99 | Sale | $2.3K |
| Karah Herdman ParschauerEVP and Chief Legal Officer2026-08-031.9K shat $24.92 | Sale10b5-1 plan | $47.3K |
| Howard HornChief Financial Officer2026-08-034.7K shat $24.92 | Sale10b5-1 plan | $117K |
| Howard HornChief Financial Officer2026-07-014.7K shat $33.13 | Sale10b5-1 plan | $155.6K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on RARE
Follow Ultragenyx Pharmaceutical Inc (RARE) by email
New trades in Ultragenyx Pharmaceutical Inc (RARE) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.